Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 10/2011

01-10-2011 | Original Article

Expression of IFN-γ and IL-4 in the Esophageal Mucosa of Patients with Reflux Esophagitis and Barrett’s Esophagus and Their Relationship with Endoscopic and Histologic Grading

Authors: Ying-Qiang Zhong, Ying Lin, Zhe Xu

Published in: Digestive Diseases and Sciences | Issue 10/2011

Login to get access

Abstract

Introduction

This study investigated the expression of interferon-γ (IFN-γ) and interleukin-4 (IL-4) in the esophageal biopsies from patients with reflux esophagitis (RE) and Barrett’s esophagus (BE) and their relationships with endoscopic grading and histologic grading.

Methods

Ninety individuals were recruited (30 RE, 30 BE, and 30 normal control) and underwent upper gastrointestinal endoscopy with esophageal biopsy. Immunohistochemistry was used to semi-quantitatively detect the expression of IFN-γ and IL-4 in the specimens.

Results

IFN-γ was overexpressed in BE and RE compared with the control (P < 0.01), whereas IL-4 was up-regulated in BE compared with RE and control (P < 0.01). A positive correlation between the level of IFN-γ and the endoscopic grading (r = 0.509, P < 0.01) and histologic grading of RE (r = 0.493, P < 0.01) was observed.

Conclusions

Th1 and Th2 immune responses play different roles in the development of RE and BE. Th1 immune response is the major pathway for RE development, whereas both Th1 and Th2 immune responses are implicated in BE pathogenesis. The expression of IFN-γ is associated with the endoscopic and histologic grading of RE.
Literature
1.
Shapiro M, Green C, Faybush EM, et al. The extent of oesophageal acid exposure overlap among the different gastro-oesophageal reflux disease groups. Aliment Pharmacol Ther. 2006;23:321–329.PubMedCrossRef
2.
Shalauta MD, Saad R. Barrett’s esophagus. Am Fam Physician. 2004;69:2113–2118.PubMed
3.
Fitzgerald RC, Onwuegbusi BA, Bajaj-Elliott M, et al. Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut. 2002;50:451–459.PubMedCrossRef
4.
Moons LM, Kusters JG, Bultman E, et al. Barrett’s oesophagus is characterized by a predominantly humoral inflammatory response. J Pathol. 2005;207:269–276.PubMedCrossRef
5.
El Chartouni C, Rehli M. Comprehensive analysis of TLR4-induced transcriptional responses in interleukin 4-primed mouse macrophages. Immunobiology. 2010;215:780–787.PubMedCrossRef
6.
Teloni R, Giannoni F, Rossi P, et al. Interleukin-4 inhibits cyclo-oxygenase-2 expression and prostaglandin E production by human mature dendritic cells. Immunology. 2007;120:83–89.PubMedCrossRef
7.
Schroder K, Hertzog PJ, Ravasi T, et al. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75:163–189.PubMedCrossRef
8.
Choi P, Reiser H. IL-4: role in disease and regulation of production. Clin Exp Immunol. 1998;113:317–319.PubMedCrossRef
9.
Borghaei RC, Rawlings PL Jr, Mochan E. Interleukin-4 suppression of interleukin-1-induced transcription of collagenase (MMP-1) and stromelysin 1 (MMP-3) in human synovial fibroblasts. Arthritis Rheum. 1998;41:1398–1406.PubMedCrossRef
10.
Corcoran ML, Stetler-Stevenson WG, Brown PD, et al. Interleukin 4 inhibition of prostaglandin E2 synthesis blocks interstitial collagenase and 92-kDa type IV collagenase/gelatinase production by human monocytes. J Biol Chem. 1992;267:515–519.PubMed
11.
Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172–180.PubMedCrossRef
12.
Ismail-Beigi F, Horton PF, Pope CE II. Histological consequences of gastroesophageal reflux in man. Gastroenterology. 1970;58:163–174.PubMed
13.
Lin Y, Buckhaults PJ, Lee JR, et al. Association of the actin-binding protein transgelin with lymph node metastasis in human colorectal cancer. Neoplasia. 2009;11:864–873.PubMed
14.
Isomoto H, Wang A, Mizuta Y, et al. Elevated levels of chemokines in esophageal mucosa of patients with reflux esophagitis. Am J Gastroenterol. 2003;98:551–556.PubMedCrossRef
15.
O’Riordan JM, Abdel-latif MM, Ravi N, et al. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol. 2005;100:1257–1264.PubMedCrossRef
16.
Yamaguchi T, Yoshida N, Tomatsuri N, et al. Cytokine-induced neutrophil accumulation in the pathogenesis of acute reflux esophagitis in rats. Int J Mol Med. 2005;16:71–77.PubMed
17.
Yoshida N, Uchiyama K, Kuroda M, et al. Interleukin-8 expression in the esophageal mucosa of patients with gastroesophageal reflux disease. Scand J Gastroenterol. 2004;39:816–822.PubMedCrossRef
18.
Fitzgerald RC, Abdalla S, Onwuegbusi BA, et al. Inflammatory gradient in Barrett’s oesophagus: implications for disease complications. Gut. 2002;51:316–322.PubMedCrossRef
19.
Farthing MJ, Fitzgerald R, Zhang ZW. Acid, helicobacter and immunity: a new paradigm for oesophagogastric cancer. J Physiol Paris. 2001;95:423–427.PubMedCrossRef
Metadata
Title
Expression of IFN-γ and IL-4 in the Esophageal Mucosa of Patients with Reflux Esophagitis and Barrett’s Esophagus and Their Relationship with Endoscopic and Histologic Grading
Authors
Ying-Qiang Zhong
Ying Lin
Zhe Xu
Publication date
01-10-2011
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 10/2011
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-011-1696-9

Other articles of this Issue 10/2011

Digestive Diseases and Sciences 10/2011 Go to the issue

Original Article

Validation of the Psychometric Hepatic Encephalopathy Score (PHES) for Identifying Patients with Minimal Hepatic Encephalopathy

Original Article

Consensus Interferon Used to Treat Prior Partial-Responders to Pegylated Interferon Plus Ribavirin

Original Article

Fecal Detection of Mycobacterium avium Paratuberculosis Using the IS900 DNA Sequence in Crohn’s Disease and Ulcerative Colitis Patients and Healthy Subjects

Original Article

Enhanced Expression of CXCL13 in Human Helicobacter pylori-Associated Gastritis

Original Article

Feasibility of Forward-Viewing Upper Endoscopy for Detection of the Major Duodenal Papilla

Original Article

Aberrant CpG Island Hypermethylation and Down-Regulation of Oct-6 mRNA Expression in Human Hepatocellular Carcinoma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits